Fig. 7: Comparison of the effectiveness of OV-A4-IgG2b versus OV- A4-IgG3 in a fully immunocompetent mouse GBM model. | Nature Communications

Fig. 7: Comparison of the effectiveness of OV-A4-IgG2b versus OV- A4-IgG3 in a fully immunocompetent mouse GBM model.

From: An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma

Fig. 7

a Survival of CT2A tumor-bearing C57BL/6 immunocompetent mice treated with vehicle control, OV-Q1, OV-A4-IgG2b, or OV-4-IgG3. b Survival of CT2A tumor-bearing C57BL/6 immunocompetent mice treated with vehicle control, OV-Q1, or OV-A4-IgG2b in the presence or absence of NK cell depletion. c Survival of CT2A tumor-bearing C57BL/6 immunocompetent mice treated with vehicle control, OV-Q1, or OV-A4-IgG2b in the presence or absence of macrophage depletion. Survival was estimated by the Kaplan–Meier method and compared by two-side log-rank test. d−f Intracranial infiltration of NK cells (CD3−NKp46+) (d), macrophages (F4/80+CD45highCD11b+) (e), and T cells (CD3+NKp46−) (f) in CT2A-bearing mice measured by flow cytometry 3 days after virus injection (n = 5 animals). g Viral production of OV-Q1-, OV-A4-IgG2b-, and OV-A4-IgG3-treated mice. h CD69 expression in NK cells isolated from mouse brains 3 days after virus injection. Representative flow cytometric plots of each group (n = 5 animals). i Quantification of CD69 expression in NK cells in (h). j In vivo macrophage phagocytosis of GBM-expressing CT2A cells after oHSV treatment. Representative flow cytometric plots of each group (n = 6 animals). k Quantification of macrophage phagocytosis of GBM-expressing CT2A cells in (j). l Red blood cell counts in peripheral blood after i.c. injection of OV-A4-IgG2b or i.p. injection of purified A4-IgG2b (n = 6 mice). For (d−g), (i) and (k, l), one-way ANOVA with P values corrected for multiple comparisons by the Bonferroni test. Data are presented as mean values ± SD.

Back to article page